Diabetes

Cardiovascular Disease May Benefit From Chinese Medicine

Cardiovascular Disease May Benefit From Chinese Medicine

Herbal alternatives used in traditional Chinese medicine may help treat or prevent cardiovascular disease.

Systolic Blood Pressure Variability Independently Predicts CV Events and Death in Diabetes

Systolic Blood Pressure Variability Independently Predicts CV Events and Death in Diabetes

By

Visit-to-visit systolic blood pressure variability may be a better predictor of cardiovascular events and death than traditional risk factors.

Statins May Increase Risk for Mortality in Type 2 Diabetes

Statins May Increase Risk for Mortality in Type 2 Diabetes

By

In a study,patients with type 2 diabetes presented better glycemic control and had higher risk for mortality when not taking statins.

Cardiovascular Stress in Type 2 Diabetes Reduced With Canagliflozin

Cardiovascular Stress in Type 2 Diabetes Reduced With Canagliflozin

By

American Diabetes Association presented a study that Canagliflozin could possibly decrease cardiovascular stress in older patients with type 2 diabetes.

Cardiovascular Events Reduced With Intensive Blood Pressure Control

Cardiovascular Events Reduced With Intensive Blood Pressure Control

By

Intensive systolic blood pressure treatment outcomes were similar between groups of patients with prediabetes and with normal fasting blood glucose levels.

CV Risks in Obesity and Diabetes Not Increased With Nalxtrexone/Bupropion

CV Risks in Obesity and Diabetes Not Increased With Nalxtrexone/Bupropion

By

Two studies found that extended-release naltrexone/bupropion did not increase cardiovascular risks for patients with type 2 diabetes.

Intensive Glucose Control in Diabetes Reduces Kidney and Eye Events

Intensive Glucose Control in Diabetes Reduces Kidney and Eye Events

By

Kidney and eye events in type 2 diabetes were reduced with more intensive glucose control.

Refill Synchronization Beneficial for Medication Adherence

Refill Synchronization Beneficial for Medication Adherence

Appointment-based models improve medication-taking behavior.

Assessing Mortality Risks in CVD, T2DM vs CKD

Assessing Mortality Risks in CVD, T2DM vs CKD

By

Chronic kidney increases the risk of mortality in patients with cardiovascular disease.

Sitagliptin Improves Triglycerides and Glucose Tolerance

Sitagliptin Improves Triglycerides and Glucose Tolerance

By

Sitagliptin improved several lipid parameters for men who were overweight and had prediabetes.

Dapagliflozin May Benefit Progression of Atherosclerosis

Dapagliflozin May Benefit Progression of Atherosclerosis

By

Dapagliflozin improved endothelial function in patients with type 2 diabetes.

Glucagon-Like Peptide-1 Receptor Agonists May Lower Cardiovascular Risk in Type 2 Diabetes

Glucagon-Like Peptide-1 Receptor Agonists May Lower Cardiovascular Risk in Type 2 Diabetes

By

Glucagon-like peptide-1 receptor agonist therapy was associated with lower risk for acute MI, stroke, and all-cause mortality.

Cardiovascular and Mortality Risk Reduction in Type 1 Diabetes

Cardiovascular and Mortality Risk Reduction in Type 1 Diabetes

By

There was a steep graded association between controlled cardiovascular risk factors and outcomes in patients with type 1 diabetes.

Overweight/Obesity Affects Brain Function in Type 2 Diabetes

Overweight/Obesity Affects Brain Function in Type 2 Diabetes

By

Overweight or obese patients with type 2 diabetes mellitus are more likely to show severe and progressive brain function and cognition abnormalities.

Diabetes Risk Predicted by Cardiometabolic Disease Staging Score

Diabetes Risk Predicted by Cardiometabolic Disease Staging Score

The Cardiometabolic Disease Staging score can effectively quantify the risk of diabetes and predict the effectiveness of weight-loss therapy for preventing diabetes in overweight and obese patients.

Fasting vs Nonfasting Lipid Values and Cardiovascular Risk: Q&A With Advisory Board Member, Eliot Brinton, MD

Fasting vs Nonfasting Lipid Values and Cardiovascular Risk: Q&A With Advisory Board Member, Eliot Brinton, MD

By

Eliot Brinton, MD, FAHA, FNLA, president and director of the Utah Lipid Center, discusses the benefits of fasting lipid profiles in predicting cardiovascular risk.

Lower HbA1c Post-PCI Promotes Better Outcomes in Diabetes

Lower HbA1c Post-PCI Promotes Better Outcomes in Diabetes

By

Patients with HbA1c levels had lower 7-year incidence of major adverse cardiac and cerebrovascular events compared with patients with higher HbA1c levels.

Atrial Fibrillation Risk Reduced With Diabetes Medications

Atrial Fibrillation Risk Reduced With Diabetes Medications

By

Thiazolidinediones reduced the risk of atrial fibrillation by 30% in an analysis of pooled data from 7 studies.

Sacubitril/Valsartan Improves Glycemic Control in Comorbid Heart Failure and Diabetes

Sacubitril/Valsartan Improves Glycemic Control in Comorbid Heart Failure and Diabetes

By

HbA1c decreased by 0.16% in the enalapril group vs 0.26% in the sacubitril/valsartan group.

Post-Cardiac Transplantation Empagliflozin Use Associated With Metabolic Benefits in T2D

Post-Cardiac Transplantation Empagliflozin Use Associated With Metabolic Benefits in T2D

By

Patients undergoing empagliflozin therapy experienced a significant reduction in weight and BMI.

CVD Risk Predicted By Fasting Pancreatic Polypeptide in Type 2 Diabetes

CVD Risk Predicted By Fasting Pancreatic Polypeptide in Type 2 Diabetes

By

Fasting pancreatic polypeptide may be a marker for macrovascular disease.

Mitigating Poor Cardiovascular Outcomes in Diabetes Using Angiography

Mitigating Poor Cardiovascular Outcomes in Diabetes Using Angiography

By

Patients with diabetes had more CV risk factors and higher rates of noninvasive testing positivity as well as 60-day aspirin, statin, ACE inhibitor, and ARB use.

Acute Coronary Syndrome Risk Reduced With Pioglitazone in Insulin Resistance Post-Stroke

Acute Coronary Syndrome Risk Reduced With Pioglitazone in Insulin Resistance Post-Stroke

By

Pioglitazone reduced the risk of acute coronary syndromes, including type 1 myocardial infarction.

ST-Segment Elevation Myocardial Infarction Symptom Presentation With Diabetes

ST-Segment Elevation Myocardial Infarction Symptom Presentation With Diabetes

By

Patients with diabetes presented with ST-segment elevation myocardial infarction symptoms, on average, 50 minutes later than patients without diabetes.

Diabetes Increases Risk of Adverse Outcomes in Heart Failure

Diabetes Increases Risk of Adverse Outcomes in Heart Failure

Researchers examined if diabetes status affected the 1-year all-cause and CVD mortality risk in patients with heart failure.

Nocturnal, Daytime Hypoglycemia Effects on Arrhythmia Risk in Type 1 Diabetes

Nocturnal, Daytime Hypoglycemia Effects on Arrhythmia Risk in Type 1 Diabetes

Compared with matched euglycemia, bradycardia was more frequent during nocturnal hypoglycemia.

Circulating Extracellular RNAs Tied to Insulin Resistance

Circulating Extracellular RNAs Tied to Insulin Resistance

Across nearly 400 ex-RNAs, 18 were associated with insulin resistance in age-, sex-, and body mass index-adjusted models.

Air Pollution Increases Risk of Type 2 Diabetes in Children

Air Pollution Increases Risk of Type 2 Diabetes in Children

A faster decline in insulin sensitivity was seen with elevated concentrations of nitrogen dioxide and particulate matter with aerodynamic diameter less than 2.5.

Animal vs Plant Protein Diets in Type 2 Diabetes

Animal vs Plant Protein Diets in Type 2 Diabetes

Diets high in animal or plant protein yielded similar clinical improvements in patients with type 2 diabetes.

Type 2 Diabetes Risk Increased With Smokeless Tobacco

Type 2 Diabetes Risk Increased With Smokeless Tobacco

Type 2 diabetes risk in users of smokeless tobacco was similar to that of regular smokers.

Sign Up for Free e-Newsletters